

# CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE CONTROVERSIES & UPDATES IN VASCULAR SURGERY

Open and Endovascular Treatment of Superior Vena Cava Syndrome of Benign Etiology

George Geroulakos, Professor of Vascular Surgery

Chairman of Department of Vascular Surgery, Attikon University Hospital, Athens




## Disclosure


I do not have any potential conflict of interest

## Background

- The increased use of central venous catheters, ports, pacemakers and defibrillators raised the incidence of benign superior vena cava syndrome (SVCS)
- 19.000 cases of SVCS occur every year in the United States
- Benign aetiologies may now comprise up to 40% of cases

## **Types of SVCS**





Type I

Type II


Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986;41:158-63.



Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

Dept. of Vascular Surgery - University of Athens

## Types of SVCS



Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 1986;41:158-63.



Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"


Dept. of Vascular Surgery - University of Athens

## Open and Endovascular Treatment of SVCS of Benign Etiology

"endovascular"[All Fields] OR
"open"[All Fields]

AND "vena cava"[All Fields]

AND ("thrombosis"[All Fields]
OR "occlusion"[All Fields])





- 9 studies (all retrospective): 136 patients
  - Central venous catheters and pacemakers 80.6%
  - Mediastinal fibrosis 13.7%
  - Other causes 5.6%
    - Post radiation fibrosis
    - Benign tumor
    - Goiter
    - Transposition of the great vessels


#### Risk Factors

- History of DVT
- Neck irradiation
- Behcet disease
- Existing dialysis fistula on the side of pacemaker leads

#### Diagnosis

- Earlier venography
- Later CT venography or MR venography

#### **Types of SVCS**



Type I 6.6%

Type II 37.7%

Type III 42.2%

Type IV **13.3%** 



#### Technical success 95.6% (132/138)

- PTA + stenting 73.6%
- PTA 17.3%
- Thrombolysis, PTA and stenting 9%

#### **Stents**

#### Self expanding

- Wallstent (Boston Scientific) 53.7%
- S.M.A.R.T (Cordis) 8.7%
- Protégé (eV3 Inc) 5%
- Zilver (Cook), Luminexx (Bard)1.2%

#### **Balloon expandable**

- Palmaz (Cordis) 20%
- Express LD (Boston Scientific) 2.5%
   Gianturco Z stent 1.2%

#### **Covered stents**

- Viabahn (W.L. Gore) 3.7%
- iCast (Atrium Maquet) 1.2%

#### **Pacemaker-Induced SVCS**

#### **Two Techniques**

- 1.Lead removal, stent implantation, and reimplantation of new leads
- 2.Plain balloon dilatation of the vein with stent placement in selected cases

#### **Results**

30- day mortality 0%


- Complications 3.6%
  - Stent migration (2 patients)
  - SVC penetration
  - Arm hematoma
  - 3<sup>rd</sup> degree heart block


#### Results

- FU 11-48 months
- Regression of the symptoms: 97.3%
- Recurrence 32 pts (26.6%)
- 58 secondary procedures
  - 48 PTAs
  - 5 PTAs with stenting
  - 3 thrombolyses and
  - 2 bypass grafts



## **Haemodialysis** catheter







- 4 studies (all retrospective): 87 patients
  - Central venous catheters and pacemakers 28.5%
  - Mediastinal fibrosis 58.4%
  - Other causes 13%
    - 5 idiopathic thromboses
    - 2 hypercoagulable state
    - 2 after ventriculoatrial shunts
    - 1 surgical excision


#### **Types of SVCS**


Right

vein









Type I 9.8%

Type II 11.5%

Type III 34.4%

Type IV 44.2%





Αγγειοχειρουργική Κλινική Ιατρικής Σχολής Πανεπιστημίου Αθηνών Π.Γ.Ν. "Αττικόν"

#### Type of graft

- Spiral saphenous vein graft 59.7% (52/87)
  - ✓ Straight (48/52): Innominate or Jugular vein to right atrial appendage
  - ✓ Bifurcated (4/52): Internal jugular vein and innominate vein to right atrial appendage
- **Externally reinforced ePTFE** 26.4% (23/87)
- Femoral vein 6.8% (6/87)
- **Human allograft** 2.3% (2/87)
- Reversed saphenous vein 1.1% (1/87)
- Venous transposition 3.4% (3/87)







#### Results

30- day mortality 0%


- 13 reoperations (15%) before discharge
  - 8 graft thrombosis
  - 3 stenoses of the graft
  - 2 patients with a mediastinal hematoma needing evacuation

#### Results

- FU 30 m 10.9 years
- Complete or partial regression of the symptoms: 93.5%
- Recurrence 24 pts (31.1%)
  - 33 secondary procedures
    - 10 PTAs
    - 11 PTAs with stenting
    - 9 thrombectomies
    - 2 graft replacements
    - 1 thrombolysis



#### Pooled primary patency after endovascular and open surgical repair for benign SVC syndrome



## **Conclusions**

 Benign SVCS syndrome is now more common as the use of indwelling catheters for dialysis and cardiac therapy expands

 Both open and endovascular treatments show good results regarding regression of the symptoms

Mid-term primary patency is similar with a significant incidence of secondary interventions

## **Conclusions**

- Endovascular is the first line of treatment for SVCS caused by intravenous devices, while surgery is most often performed for mediastinal fibrosis
- Patients who underwent surgical treatment usually presented with more severe disease
- There is a high incidence of reoperations before discharge after surgery
- Secondary interventions after initial endovascular treatment or open surgery are mainly endovascular

